TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11841931

Group type: EXPERIMENTAL
Intervention: Capecitabine (1250 mg/m2 twice daily for 14 days every 3 weeks)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: 5-FU/leucovorin (5-FU 425 mg/m2 plus leucovorin 20 mg/m2 days 1-5, every 4 weeks)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Capecitabine and 5-FU/leucovorin
Number of subjects: 1200
Study: 10565330

Group type: EXPERIMENTAL
Intervention: Perioperative nutrition support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parenteral nutrition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enteral nutrition
Number of subjects: 0
Study: 7926082

Group type: EXPERIMENTAL
Intervention: GnRH‐agonist (GnRH‐a) treatment
Number of subjects: 6

Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (age- and weight-matched ovulatory women)
Number of subjects: 6
Study: 2604961

Group type: EXPERIMENTAL
Intervention: Shofu GlasIonomer Base
Number of subjects: 3

Group type: COMPARATOR
Intervention: Ketac‐Bond Aplicap
Number of subjects: 3

Group type: COMPARATOR
Intervention: GC Dentin Cement
Number of subjects: 3
Study: 1098808

Group type: EXPERIMENTAL
Intervention: sulfinpyrazone
Number of subjects: 45

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 45
Study: 29701554

Group type: EXPERIMENTAL
Intervention: Microsurgical clipping of ruptured MCA aneurysms
Number of subjects: 46
Study: 28139830

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (100 mg/day for 7 days)
Number of subjects: 40
Study: 25888250

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 5,000 IU/dose, subcutaneously administered at 48 hours and 72 hours after acute IS
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 23751884

Group type: EXPERIMENTAL
Intervention: Hassle Free Mealtimes Triple P
Number of subjects: 96

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 96
Study: 21749851

Group type: EXPERIMENTAL
Intervention: Temporary pancreatic duct stent (5F diameter, 3 cm long, straight with unflanged inner end)
Number of subjects: 426

Group type: COMPARATOR
Intervention: No pancreatic duct stent (control group)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Temporary pancreatic duct stent
Number of subjects: 426

Group type: COMPARATOR
Intervention: No pancreatic duct stent
Number of subjects: 426
Study: 19178948

Group type: EXPERIMENTAL
Intervention: Active rTMS (20 Hz, 110% of MT, 20 trains, 10 s intertrain interval)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 41
Study: 16719606

Group type: EXPERIMENTAL
Intervention: Education intervention
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Education plus group discussion intervention
Number of subjects: 250

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 250
Study: 15278105

Group type: EXPERIMENTAL
Intervention: Dietary Weight Loss
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Diet+Exercise
Number of subjects: 316

Group type: COMPARATOR
Intervention: Exercise Training
Number of subjects: 316

Group type: COMPARATOR
Intervention: Healthy Lifestyle Controls
Number of subjects: 316
Study: 11297242

Group type: EXPERIMENTAL
Intervention: UFT (2 x 100 mg capsules) and leucovorin (2 x 15 mg tablets) administered after an overnight fast
Number of subjects: 25

Group type: COMPARATOR
Intervention: UFT (2 x 100 mg capsules) and leucovorin (2 x 15 mg tablets) administered 5 min after a high‐fat meal
Number of subjects: 25
Study: 9702571

Group type: EXPERIMENTAL
Intervention: Disposable thermometers
Number of subjects: 26350

Group type: COMPARATOR
Intervention: Electronic thermometers
Number of subjects: 26350
Study: 8018355

Group type: EXPERIMENTAL
Intervention: Fast neutron radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Photon/electron radiation
Number of subjects: 0
Study: 2791759

Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 40
Study: 55583

Group type: EXPERIMENTAL
Intervention: Transfer factor (T.F.) prepared from 5 x 10(8) lymphoid cells from 500 ml of a parent's blood
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group of 35 similar children
Number of subjects: 40
Study: 31770207

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.3 μg/kg/h)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 44
Study: 27837014

Group type: EXPERIMENTAL
Intervention: Zombie pandemic theme
Number of subjects: 89

Group type: COMPARATOR
Intervention: Natural disaster scenario
Number of subjects: 89
Study: 26021662

Group type: EXPERIMENTAL
Intervention: Full threaded, cannulated compression screws (Acutrak 6/7, ACUMED)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Partial threaded, 6.5mm or 7.3mm cannulated screws (SYNTHES)
Number of subjects: 44
Study: 23890471

Group type: EXPERIMENTAL
Intervention: Paleolithic diet
Number of subjects: 13

Group type: COMPARATOR
Intervention: Diabetes diet
Number of subjects: 13
Study: 21223501

Group type: EXPERIMENTAL
Intervention: CBT-BF+active
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CBT-BF
Number of subjects: 36

Group type: COMPARATOR
Intervention: WL control
Number of subjects: 36
Study: 19147365

Group type: COMPARATOR
Intervention: WBV-exercise on a stable platform (VibM; n=17, mean age 61.5+/‐9.2)
Number of subjects: 52

Group type: COMPARATOR
Intervention: WBV-exercise on a balance board (VibF; n=18, mean age 58.7+/‐11.0)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (Con; n=18, mean age 61.1+/‐8.5)
Number of subjects: 52
Study: 17350369

Group type: EXPERIMENTAL
Intervention: Positive culture results (n = 40)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Negative culture results (n = 14)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Duration of IABP support
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Use of multiple central catheters
Number of subjects: 54
Study: 15154945

Group type: EXPERIMENTAL
Intervention: Staged Diabetes Management (SDM) programme
Number of subjects: 340

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 340
Study: 11569481

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (4.6 g n-3 fatty acids/day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 29
Study: 9259247

Group type: EXPERIMENTAL
Intervention: Oral pamidronate (APD), 300 mg/day plus calcium 1 g/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral pamidronate (APD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 60
Study: 8512628

Group type: EXPERIMENTAL
Intervention: Milacemide 400 mg/day
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Milacemide 800 mg/day
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Milacemide 1200 mg/day
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Milacemide (all doses combined)
Number of subjects: 148
Study: 3325320

Group type: EXPERIMENTAL
Intervention: Iron protein succinylate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Iron sulphate
Number of subjects: 40
Study: 29133161

Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA) with Ropivacaine, 150 ml
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (saline solution), 150 ml
Number of subjects: 40
Study: 26781394

Group type: EXPERIMENTAL
Intervention: SPS with alcohol and povidone‐iodine before draping and an additional SPS by iodine povacrylex and isopropyl alcohol before application of the final adhesive drape
Number of subjects: 600
Study: 25495747

Group type: EXPERIMENTAL
Intervention: Primary Care Triple P (n = 34)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Wait-list control group (n = 33)
Number of subjects: 67
Study: 22809024

Group type: EXPERIMENTAL
Intervention: Resuscitating acupuncture
Number of subjects: 290

Group type: COMPARATOR
Intervention: Sham-acupoints
Number of subjects: 290
Study: 20132152

Group type: EXPERIMENTAL
Intervention: 4 mg/day irsogladine maleate (n = 150)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Placebo (n = 161)
Number of subjects: 322
Study: 18753647

Group type: EXPERIMENTAL
Intervention: Bortezomib plus melphalan and prednisone
Number of subjects: 682

Group type: COMPARATOR
Intervention: Melphalan and prednisone alone (control group)
Number of subjects: 682
Study: 15929750

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 14527077

Group type: EXPERIMENTAL
Intervention: Topical nasal corticosteroids for 8 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo saline spray for 8 weeks
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Topical nasal corticosteroids for 4 weeks followed by placebo saline spray for 4 weeks
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Placebo saline spray for 4 weeks followed by topical nasal corticosteroids for 4 weeks
Number of subjects: 28
Study: 10559704

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 10
Study: 8742912

Group type: EXPERIMENTAL
Intervention: Isradipine (5 mg, long acting slow release oral)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 1444726

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Naltrexone and supportive therapy
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Naltrexone and coping skills therapy
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 4056254

Group type: EXPERIMENTAL
Intervention: Theobromine (10 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Theophylline (5 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Theobromine and Theophylline
Number of subjects: 0
Study: 31058705

Group type: EXPERIMENTAL
Intervention: Psychoeducation intervention
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 95
Study: 29791287

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 493

Group type: COMPARATOR
Intervention: Standard chemotherapy (anthracycline and taxane) without bevacizumab
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: pCR status
Number of subjects: 493
Study: 27098821

Group type: EXPERIMENTAL
Intervention: Intervention website
Number of subjects: 3044
Study: 25710011

Group type: EXPERIMENTAL
Intervention: Surgical stabilization using Stracos
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (conservative management)
Number of subjects: 20
Study: 24252648

Group type: COMPARATOR
Intervention: Standard implementation strategy (Replicating Effective Programs, or REP)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Enhanced REP with External Facilitation
Number of subjects: 158
Study: 20429895

Group type: EXPERIMENTAL
Intervention: Yoga plus Cognitive Behavioral Therapy (CBT) smoking cessation intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wellness program plus Cognitive Behavioral Therapy (CBT) smoking cessation intervention
Number of subjects: 0
Study: 18835425

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease group
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study: 16620718

Group type: EXPERIMENTAL
Intervention: CEUS (contrast-enhanced ultrasound)
Number of subjects: 211

Group type: COMPARATOR
Intervention: US (routine ultrasound)
Number of subjects: 211
Study: 12944689

Group type: EXPERIMENTAL
Intervention: Erythrocyte GSH levels in AMI patients
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Total cholesterol and triglycerides in AMI patients
Number of subjects: 22
Study: 10795592

Group type: EXPERIMENTAL
Intervention: 1.9 Lf tetanus toxoid (0.25 ml)
Number of subjects: 200

Group type: COMPARATOR
Intervention: 3.75 Lf tetanus toxoid (0.5 ml)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups (1.9 Lf and 3.75 Lf)
Number of subjects: 200
Study: 8846172

Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Overall prognosis for the whole group
Number of subjects: 56
Study: 1538359

Group type: EXPERIMENTAL
Intervention: Count-to-10 method
Number of subjects: 85

Group type: COMPARATOR
Intervention: Other charting methods
Number of subjects: 85
Study: 6502941

Group type: EXPERIMENTAL
Intervention: L-carnitine (900 mg, p.o. daily)
Number of subjects: 12
Study: 31107327

Group type: EXPERIMENTAL
Intervention: Pedicle guider technology
Number of subjects: 32

Group type: COMPARATOR
Intervention: Freehand technique (Control)
Number of subjects: 32
Study: 29625340

Group type: EXPERIMENTAL
Intervention: Rifampicin
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Tigecycline
Number of subjects: 125
Study: 27020037

Group type: EXPERIMENTAL
Intervention: GHRP-2 test
Number of subjects: 47

Group type: COMPARATOR
Intervention: Insulin tolerance test (ITT)
Number of subjects: 47
Study: 25088835

Group type: EXPERIMENTAL
Intervention: Retrograde angioplasty (RAG)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Anterograde angioplasty (AAG)
Number of subjects: 96
Study: 22560503

Group type: EXPERIMENTAL
Intervention: First trial feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Performance feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stimulus cue presentation
Number of subjects: 0
Study: 18837470

Group type: EXPERIMENTAL
Intervention: Pol + BG (5 g beta-glucan)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pol (without beta-glucan)
Number of subjects: 12
Study: 17200680

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 127

Group type: COMPARATOR
Intervention: Calcium-containing phosphate binders
Number of subjects: 127
Study: 16084463

Group type: EXPERIMENTAL
Intervention: 300 mg intrarectal lidocaine jelly
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline jelly (placebo)
Number of subjects: 10
Study: 12034124

Group type: EXPERIMENTAL
Intervention: Manual force levels beyond 1.9 N/cm
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Manual force levels from 0.76 to 4.54 N/cm
Number of subjects: 6
Study: 10495407

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 267

Group type: COMPARATOR
Intervention: Control
Number of subjects: 267
Study: 7598153

Group type: EXPERIMENTAL
Intervention: Occupationally embedded exercise
Number of subjects: 52

Group type: COMPARATOR
Intervention: Rote exercise
Number of subjects: 52
Study: 1687485

Group type: EXPERIMENTAL
Intervention: Savoxepine (0.5 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Chlorpromazine (75 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Savoxepine (average 0.1 to 0.9 mg/d) in clinical trials
Number of subjects: 28
Study: 6660442

Group type: EXPERIMENTAL
Intervention: scopolamine-TTS
Number of subjects: 100
Study: 31791295

Group type: EXPERIMENTAL
Intervention: Routine care plus WeChat breastfeeding education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine antenatal and postnatal care (Control)
Number of subjects: 0
Study: 29478117

Group type: EXPERIMENTAL
Intervention: Posterior PECD combined with VAT
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional posterior PECD
Number of subjects: 44
Study: 27769289

Group type: EXPERIMENTAL
Intervention: Oily fish consumption (300 g/week)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Poultry (control)
Number of subjects: 200
Study: 25142075

Group type: EXPERIMENTAL
Intervention: Mistletoe extract treatment (subcutaneous injection, escalating doses, three times a week)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Best supportive care (control group)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Mistletoe extract treatment
Number of subjects: 220
Study: 23127448

Group type: EXPERIMENTAL
Intervention: Drainage treatment (group 1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No drainage treatment (group 2)
Number of subjects: 80
Study: 20567989

Group type: EXPERIMENTAL
Intervention: Keel technique
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Onlay technique
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Sublay technique
Number of subjects: 161

Group type: COMPARATOR
Intervention: General complications rate
Number of subjects: 161
Study: 17980250

Group type: EXPERIMENTAL
Intervention: AZD6140 90 mg
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: AZD6140 180 mg
Number of subjects: 990

Group type: COMPARATOR
Intervention: Clopidogrel 300 mg loading dose plus 75 mg once daily
Number of subjects: 990
Study: 15745385

Group type: EXPERIMENTAL
Intervention: Inhaled tiotropium bromide 18 microg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Inhaled Placebo
Number of subjects: 10
Study: 12479050

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.2 mg daily for four weeks
Number of subjects: 43
Study: 9469330

Group type: EXPERIMENTAL
Intervention: Perioperative treatment with one course of fluorouracil, doxorubicin, and cyclophosphamide (FAC)
Number of subjects: 441

Group type: COMPARATOR
Intervention: No further therapy (Control)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Perioperative treatment with one course of FAC
Number of subjects: 441
Study: 7897053

Group type: EXPERIMENTAL
Intervention: Treated participants
Number of subjects: 38

Group type: COMPARATOR
Intervention: Untreated participants
Number of subjects: 38
Study: 2472521

Group type: EXPERIMENTAL
Intervention: UDCG 115 BS 5 mg p.o.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: UDCG 115 BS 10 mg p.o.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Continuous treatment with 10 mg UDCG 115 BS/day for greater than 5 days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Dobutamine (optimal dose)
Number of subjects: 25
Study: 438015

Group type: EXPERIMENTAL
Intervention: Eucapnic hyperventilation at body conditions (0 heat flux)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Eucapnic hyperventilation with decreased water content and temperature of the inspirate
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Decreasing thermal burden by reducing ventilation (VE)
Number of subjects: 8
Study: 31894022

Group type: EXPERIMENTAL
Intervention: Human gamma globulin (HGG)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (comprehensive treatment)
Number of subjects: 80
Study: 28836528

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with diode laser (gallium aluminum arsenide, 810 nm, 0.1 W)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40
Study: 26239948

Group type: EXPERIMENTAL
Intervention: Ferric Citrate (FC)
Number of subjects: 441

Group type: COMPARATOR
Intervention: Active Control (AC) (sevelamer carbonate and/or calcium acetate)
Number of subjects: 441
Study: 23670096

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment
Number of subjects: 910

Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 910
Study: 20800897

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 19137506

Group type: EXPERIMENTAL
Intervention: Home visits from a project nurse or medical doctor (10 visits during the first 2 years after discharge)
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Home visits from a project nurse or medical doctor
Number of subjects: 249

Group type: COMPARATOR
Intervention: Control group (no home visits)
Number of subjects: 249
Study: 18219837

Group type: EXPERIMENTAL
Intervention: Fexofenadine hydrochloride, 15 mg, twice daily for 8 days
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Fexofenadine hydrochloride, 30 mg, twice daily for 8 days
Number of subjects: 393

Group type: COMPARATOR
Intervention: Placebo, twice daily for 8 days
Number of subjects: 393
Study: 14742305

Group type: EXPERIMENTAL
Intervention: Pranlukast 300 mg twice a day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 11549425

Group type: COMPARATOR
Intervention: Observation only (A)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) 450 mg/m2 plus levamisol (B)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) 600 mg/m2 (C)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 127
Study: 9559784

Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: 1% imiquimod cream
Number of subjects: 279

Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 279
Study: 7942076

Group type: EXPERIMENTAL
Intervention: 2 mg estradiol valerate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2 mg micronized estradiol
Number of subjects: 20
Study: 3365527

Group type: EXPERIMENTAL
Intervention: Orudis (simple ketoprofen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oruvail (slow release ketoprofen)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 0
Study: 31999314

Group type: EXPERIMENTAL
Intervention: R20EFV600
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: R20EFV800
Number of subjects: 98

Group type: COMPARATOR
Intervention: R10EFV600
Number of subjects: 98
Study: 29324968

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI) for 10 years (n = 2,406)
Number of subjects: 4790

Group type: COMPARATOR
Intervention: Diabetes support and education (DSE) for 10 years (n = 2,384)
Number of subjects: 4790

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 4790

Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 4790